$16.02
2.46% today
Nasdaq, Aug 04, 09:49 pm CET
ISIN
US89422G1076
Symbol
TVTX

Travere Therapeutics Inc Stock price

$15.63
+0.92 6.25% 1M
-4.59 22.70% 6M
-1.79 10.28% YTD
+6.39 69.16% 1Y
-7.28 31.78% 3Y
-4.53 22.47% 5Y
-16.31 51.06% 10Y
-19.47 55.47% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
+0.18 1.17%
ISIN
US89422G1076
Symbol
TVTX
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.4b
Net debt
$57.2m
Cash
$322.2m
Shares outstanding
88.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.1 | 3.5
EV/Sales
5.3 | 3.6
EV/FCF
negative
P/B
42.3
Financial Health
Equity Ratio
9.9%
Return on Equity
-544.3%
ROCE
-61.4%
ROIC
-125.8%
Debt/Equity
11.6
Financials (TTM | estimate)
Revenue
$273.5m | $400.2m
EBITDA
$-180.3m | $86.1m
EBIT
$-225.1m | $-99.0m
Net Income
$-226.7m | $-98.2m
Free Cash Flow
$-267.2m
Growth (TTM | estimate)
Revenue
111.0% | 71.6%
EBITDA
44.8% | 140.1%
EBIT
38.1% | 61.3%
Net Income
-40.7% | 69.5%
Free Cash Flow
21.1%
Margin (TTM | estimate)
Gross
96.0%
EBITDA
-65.9% | 21.5%
EBIT
-82.3%
Net
-82.9% | -24.5%
Free Cash Flow
-97.7%
More
EPS
$-2.6
FCF per Share
$-3.0
Short interest
14.6%
Employees
380
Rev per Employee
$610.0k
Show more

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,032 stocks worldwide.

Travere Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Travere Therapeutics Inc forecast:

19x Buy
86%
3x Hold
14%

Analyst Opinions

22 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Travere Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
274 274
111% 111%
100%
- Direct Costs 11 11
39% 39%
4%
263 263
116% 116%
96%
- Selling and Administrative Expenses 228 228
1% 1%
83%
- Research and Development Expense 215 215
6% 6%
79%
-180 -180
45% 45%
-66%
- Depreciation and Amortization 45 45
22% 22%
16%
EBIT (Operating Income) EBIT -225 -225
38% 38%
-82%
Net Profit -227 -227
41% 41%
-83%

In millions USD.

Don't miss a Thing! We will send you all news about Travere Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Travere Therapeutics Inc Stock News

Neutral
Business Wire
5 days ago
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can b...
Neutral
Business Wire
24 days ago
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 17 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 121,700 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 20...
Neutral
Business Wire
about 2 months ago
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 81,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 201...
More Travere Therapeutics Inc News

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 380
Founded 2008
Website travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today